Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study

Jiming Hu, Kai Xing, Yan Zhang, Miao Liu, Zhiwei Wang

Submitted to: JMIR Medical Informatics on: October 29, 2021

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.
# Table of Contents

Original Manuscript................................................................................................................................. 5  
Supplementary Files.................................................................................................................................... 27  
Figures.......................................................................................................................................................... 28  
  Figure 1..................................................................................................................................................... 29  
  Figure 2..................................................................................................................................................... 30  
  Figure 3..................................................................................................................................................... 31  
  Figure 4..................................................................................................................................................... 32  
  Figure 5..................................................................................................................................................... 33  
  Figure 6..................................................................................................................................................... 34  
  Figure 7..................................................................................................................................................... 35
Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study

Jiming Hu1; Kai Xing2; Yan Zhang2; Miao Liu3; Zhiwei Wang4

1School of Information Management, Wuhan University Wuhan CN
2Department of Clinical Laboratory, Renmin Hospital of Wuhan University Wuhan CN
3Department of Pediatrics, Renmin Hospital of Wuhan University Wuhan CN
4Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University Wuhan CN

Corresponding Author:
Miao Liu
Department of Pediatrics, Renmin Hospital of Wuhan University
No. 9 Zhang Zhidong Road, Wuchang District
Wuhan
CN

Abstract

Background: Tyrosinase inhibitors (TKIs) have achieved revolutionary results in the treatment of a wide range of tumors, which have brought out a lot of literature in this field every year. And some reviews provide a great value for us to understand TKIs. However, there is a lack of studies on the knowledge structure and bibliometric analysis in TKIs research.

Objective: This paper aims to investigate the knowledge structure, hotspots, and trends of evolution of the field of TKIs by co-word analysis and literature visualization.

Methods: We obtained all academic papers about TKIs published in 2016-2020 from the Web of Science. Based on counting keywords from those papers, we generated the co-word networks by extracting the co-occurrence relationships between keywords, and segmented communities to identify the sub-directions of TKIs research by calculating the network metrics of the overall and local networks. We also mapped the association network topology, including the network within and between TKIs sub-directions, to reveal the association and structure among varied sub-directions. Finally, evolution venation and strategic diagram were generated to reveal the trends of TKIs research.

Results: We obtained 6,782 unique words (total frequency 26,175) from 5,584 paper captions. Finally, 296 high-frequency words were selected with a threshold of 10 after discussion, the total frequency of which accounted for 65.41%. The analysis of burst disciplines revealed a variable number of burst words of TKIs research every year, especially in 2019 and 2020, such as HER2, Pyrotinib, Next-generation Sequencing, Immunotherapy, ALK-TKI, ALK Rearrangement, etc. By network calculation, the TKIs co-word network was divided into six communities: C1-Non-small Cell Lung Cancer, C2-Targeted Therapy, C3-Chronic Myeloid Leukemia, C4-HER2, C5-Pharmacokinetics, and C6-ALK. The venation diagram revealed several clear and continuous evolution trends, such as Non-small Cell Lung Cancer venation, Chronic Myeloid Leukemia venation, Renal Cell Carcinoma venation, Chronic Lymphocytic Leukemia venation, etc. In the strategic diagram, C1-Non-small Cell Lung Cancer was the core direction located in the first quadrant, C2-Targeted Therapy was exactly at the junction of the first and fourth quadrants that meant C2 was developing, and C3-Chronic Myeloid Leukemia, C4-HER2, and C5-Pharmacokinetics were all immature that all located in the third quadrant.

Conclusions: Using co-word analysis and literature visualization, we revealed the hotspots, knowledge structure, and trends of evolution of TKIs research during 2016-2020. TKIs research mainly focused on targeted therapies against varied tumors, particularly against NSCLC. The attention on CML and pharmacokinetics was gradually decreasing, but the heat of HER2 and ALK was rapidly increasing. TKIs research had shown a clear development path: TKIs research was disease-focused and revolved around "gene targets/targeted drugs/resistance mechanisms". Our outcomes will provide sound and effective support to researchers, funders, policymakers, and clinicians.

(JMIR Preprints 29/10/2021:34548)
DOI: https://doi.org/10.2196/preprints.34548
Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?
   ✓ Please make my preprint PDF available to anyone at any time (recommended).
     - Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.
     - Only make the preprint title and abstract visible.
     - No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?
   ✓ Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).
   - Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to everyone.
   - Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in the PubMed Now! service, my accepted manuscript PDF will automatically be made openly available.
Original Manuscript
Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study

Jiming Hu*, Kai Xing#, Yan Zhang#, Miao Liu*, and Zhiwei Wang*

List of contributors
1. Jiming Hu*
   E-mail: hujiming@whu.edu.cn;
   Tel: +86-18995621959;
   Address: School of Information Management, Wuhan University, Wuhan, Hubei, China, 430072

2. Kai Xing
   E-mail: xingkai@whu.edu.cn;
   Tel: +86-18502731887;
   Address: Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China, 430060

3. Yan Zhang
   E-mail: peneyyan@mail.ustc.edu.cn;
   Tel: +86-15327156829;
   Address: Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China, 430060.

4. Miao Liu*
   E-mail: liumiao915@whu.edu.cn;
   Tel: +86-13349879352;
   Address: Department of Pediatrics, Renmin Hospital of Wuhan University, Wuhan, China, 430060.

5. Zhiwei Wang*
   E-mail: wangzhiwei@whu.edu.cn;
   Tel: +86-13995628899;
   Address: Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China, 430060
Abstract

Background
Tyrosinase inhibitors (TKIs) have achieved revolutionary results in the treatment of a wide range of tumors, which have brought out a lot of literature in this field every year. And some reviews provide a great value for us to understand TKIs. However, there is a lack of studies on the knowledge structure and bibliometric analysis in TKIs research.

Objective
This paper aims to investigate the knowledge structure, hotspots, and trends of evolution of the field of TKIs by co-word analysis and literature visualization.

Methods
We obtained all academic papers about TKIs published in 2016-2020 from the Web of Science. Based on counting keywords from those papers, we generated the co-word networks by extracting the co-occurrence relationships between keywords, and segmented communities to identify the sub-directions of TKIs research by calculating the network metrics of the overall and local networks. We also mapped the association network topology, including the network within and between TKIs sub-directions, to reveal the association and structure among varied sub-directions. Finally, evolution venation and strategic diagram were generated to reveal the trends of TKIs research.

Results
We obtained 6,782 unique words (total frequency 26,175) from 5,584 paper captions. Finally, 296 high-frequency words were selected with a threshold of 10 after discussion, the total frequency of which accounted for 65.41%. The analysis of burst disciplines revealed a variable number of burst words of TKIs research every year, especially in 2019 and 2020, such as HER2, Pyrotinib, Next-generation Sequencing, Immunotherapy, ALK-TKI, ALK Rearrangement, etc. By network calculation, the TKIs co-word network was divided into six communities: C1-Non-small Cell Lung Cancer, C2-Targeted Therapy, C3-Chronic Myeloid Leukemia, C4-HER2, C5-Pharmacokinetics, and C6-ALK. The venation diagram revealed several clear and continuous evolution trends, such as Non-small Cell Lung Cancer venation, Chronic Myeloid Leukemia venation, Renal Cell Carcinoma venation, Chronic Lymphocytic Leukemia venation, etc. In the strategic diagram, C1-Non-small Cell Lung Cancer was the core direction located in the first quadrant, C2-Targeted Therapy was exactly at the junction of the first and fourth quadrants that meant C2 was developing, and C3-Chronic Myeloid Leukemia, C4-HER2, and C5-Pharmacokinetics were all immature that all located in the third quadrant.

Conclusions
Using co-word analysis and literature visualization, we revealed the hotspots, knowledge structure, and trends of evolution of TKIs research during 2016-2020. TKIs research mainly focused on targeted therapies against varied tumors, particularly against NSCLC. The attention on CML and pharmacokinetics was gradually decreasing, but the heat of HER2 and ALK was rapidly increasing. TKIs research had shown a clear development path: TKIs research was disease-focused and revolved around "gene targets/targeted drugs/resistance mechanisms". Our outcomes will provide sound and effective support to researchers, funders, policymakers, and clinicians.

Keywords: TKIs, co-word analysis, literature visualization, NSCLC, targeted therapy, CML, topics distribution, HER2, pharmacokinetics,
1. Introduction

Tyrosine kinases (TKs) are a collective term for dozens of kinases encoded by multiple genes, which can phosphorylate tyrosine residues in cells. Based on varied cellular localizations, the TKs family is divided into receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (non-RTKs). RTKs consist of 20 subfamilies (e.g., epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR)), whereas non-RTKs include 10 subfamilies such as ABL, SRC, and CSK. TKs have the common activity to catalyze the transfer of γ-phosphate groups on adenosine triphosphate (ATP) to the tyrosine residues of a variety of target proteins, and this process plays a key role in signal transduction in the cell. Abnormal activities of TKs are closely associated with proliferation, invasion, metastasis, apoptosis, and tumor angiogenesis in non-small cell lung cancer (NSCLC), chronic myeloid leukemia (CML), and many other tumors. Therefore, TKs have become excellent targets for tumor therapy.

Tyrosine kinase inhibitors (TKIs) are referred to as a class of small-molecule compounds that can specifically inhibit TKs. They can penetrate through the cell membrane and block the signaling pathway of tumor proliferation, and some TKIs can also inhibit angiogenesis. TKIs have revolutionized the treatment of a variety of tumors, for example, imatinib has been a typical pioneer in successfully translating oncogene research into molecular targeted therapy. Now, TKIs have developed to the fourth generation, which aims to overcome drug resistance due to mutations of T790M and C797S. More than 30 small-molecule TKIs have been approved for marketing by the U.S. Food and Drug Administration (FDA), and hundreds of drug candidates are in various stages of clinical trials. Therefore, this article aims to understand the development process of TKIs research, identify the main research directions, and analyze the potential research hotspots.

Co-word analysis is a content analysis method to study the knowledge structure and evolutionary patterns of various fields. It can facilitate researchers to identify hotspots, composition, paradigms, and evolution of a field by calculating the word pairs and co-occurrence of noun phrases in the literature. This method has been used widely in medical bibliometric analysis, such as precision medicine, neonatal ischemic-hypoxic encephalopathy, stem cell research, neural stem cells, tumor immunotherapy, disaster medicine, medical big data, surgical robotics, epilepsy genetics, etc. We propose to use the co-word analysis to explore the knowledge structure, evolution trends, and associations among sub-topics of TKIs research, aiming to help clinicians and scholars have a better understanding of TKIs and to give suggestions for research and usage of TKs.

2. Literature review

2.1 Background

In recent years, targeted therapies have become a hotspot in the development of anti-tumor drugs with their advantages of high selectivity and low side effects. TKIs are revolutionary targeted drugs that inhibit tumor proliferation by interfering with or inhibiting specific proteins within cancer cells, thus exerting prominent anti-tumor effects. Among them, imatinib was the first targeted antitumor drug, which was first approved in 2001 for the treatment of BCR-ABL-positive Philadelphia chromosome-positive CML. And then, the first, second, and third-generation TKIs, represented by gefitinib, dasatinib, and osimertinib, have been validated in hundreds of clinical trials and approved for marketing.

Genetic testing has been developed rapidly. Next-generation sequencing (NGS) allows for the sequencing genome and exome within days and makes it possible to identify patients with druggable mutations quickly and precisely. Meanwhile, multidisciplinary collaboration between pharmacology and clinical science has brought a leap forward in basic research and clinical applications of TKIs. First, tumor-targeted therapies are the most established area for TKIs, especially in the treatment of lung cancer, leukemia, and advanced NSCLC. It’s demonstrated that TKIs improved the quality of life and extend survival in patients with advanced NSCLC. Imatinib and gefitinib have become first-line drugs due to their outstanding clinical efficacy in patients with BCR-ABL-positive CML. Second, clinical trials of various drugs targeting HER2 and ALK, etc.
trastuzumab\textsuperscript{34, 35}, patolizumab\textsuperscript{36}, ceritinib\textsuperscript{37}) have manifested excellent effects. Third, pharmacokinetics is another focus of TKIs research. Optimization and selectivity study is an important direction for continuing clinical trials after the launch of many TKIs. And individualized blood concentration monitoring is also important for patients with poor efficacy or severe side effects\textsuperscript{38}.

2.2 Previous efforts

In recent years, TKIs have been widely used for tumor-targeted therapies. Numerous research efforts helped clinicians and scholars better understand TKIs and facilitated the clinical translation of study outcomes.

Based on recent reviews, the current status of TKIs research is summarized as follows: First, TKIs resistance is becoming increasingly prominent, of which genetic mutations (e.g., T790M\textsuperscript{39, 40}, C797S\textsuperscript{13}, D761Y\textsuperscript{41}, L747S\textsuperscript{42}) are the main cause. It has become a key direction to find new molecular mechanisms of TKIs resistance and to establish individualized dosing regimens. Second, the application of drugs such as Erlotinib\textsuperscript{43}, Osimertinib\textsuperscript{15, 33}, and Gefitinib\textsuperscript{44} has gradually matured and occupied an important position in the treatment of various tumors such as NSCLC\textsuperscript{11, 12}. Third, drugs targeting HER2 and ALK continue to emerge, which offers new hope for solving the plague of drug resistance\textsuperscript{45, 46}. To date, hundreds of new TKIs candidates are in various stages of clinical research\textsuperscript{47}.

2.3 The rationale for the study

Research on TKIs continues to grow to benefit more patients. However, there is still a lot of uncharted territories to explore in TKIs research. How to discover new biomarkers of TKIs? How to select TKIs with better clinical effects and fewer side effects for targeted therapy? How to overcome multidrug resistance in patients with tumors? All these questions need scientific bibliometric analysis based on the results of TKIs research. The purpose of our study is to address the following questions:

(1) What is the overall knowledge structure of TKIs research?
(2) What are the sub-directions of TKIs research and how do they interact with each other?
(3) What are the evolutionary status and development trends of TKIs research in the temporal dimension?

3. Methods

3.1 Data collection and processing

It is well known that Web of Science Core Collection (WOSCC) is the most extensive and comprehensive academic literature database, so we used subjects (including "Tyrosine kinase inhibitor, Tyrosine kinase inhibitors, TKI, TKIs, Tyrosine kinases inhibitors, Tyrosine kinases inhibitors") in WOSCC to precisely search all literature about TKIs by limiting the period to 2016-2020 and the literature types to journal papers, reviews and conference papers. The specific search formula is “(TS= ("Tyrosine kinase inhibitor" OR "Tyrosine kinase inhibitors" OR "TKI" OR "TKIs" OR "Tyrosine kinases inhibitors" OR "Tyrosine kinases inhibitor")) AND LANGUAGE: (English) Refined by: DOCUMENT TYPES: ( ARTICLE OR REVIEW OR PROCEEDINGS PAPER ) Timespan: 2016-2020. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC”.

A total of 13,895 documents were retrieved and exported in Tab-delimited (Win) format. Next, the records containing search terms in the titles or keywords were retained, while the records without keywords and the records with search terms appearing only in the abstracts were excluded\textsuperscript{48, 49}. Finally, 5,584 records were obtained for the subsequent co-word network analysis. (Figure 1)

Since there are irregularities and inconsistencies in the writing of keywords submitted by the authors themselves in WOS, it is necessary to pre-process them. First, this paper aims to depict the research status of TKIs by using other terms associated with TKIs, so TKI itself, the synonyms, and
hyponyms of TKI were removed. Keywords whose meaning is broad (e.g., review, development, problem, etc.) were also removed. Secondly, the co-word analysis generally targets high-frequency keywords and their relationships, while keywords with very low frequencies cannot reflect the main direction of the current research. Therefore, this paper firstly generated a list of keywords by frequency descending order and then defined the threshold of high-frequency keywords according to the cumulative percentage of frequencies in the list. Third, keywords with frequencies below the threshold were merged into the words with the closest meanings, and words with the same meaning and different forms were also merged, such as “BCR-ABL TKI” to “BCR-ABL” and “Epidermal Growth Factor Receptor” to “EGFR”. Fourth, after de-duplicating the merged keywords, a new list of keyword frequencies was generated.

**Figure 1.** Search procedure for documents in TKIs research. DE: descriptor; TI: title; WOSCC: Web of Science Core Collection.

### 3.2 Network construction and analysis

The keywords in a paper are an accurate description of its main content, so mining keywords and their relationships can help reveal the hidden connotation of a research field. If two words co-occur in the same connotation unit (e.g., keywords in a paper), they are related or similar in connotation and have consistency in connotation expression. Their co-occurrence frequency is equal to the number of papers that contain them at the same time, and the greater the frequency, the stronger the semantic association between them. By constructing co-word networks and performing structural analysis and visualization, co-word analysis can effectively reveal the underlying connotations, research structures, and even evolutionary trends of a research field.

In this paper, the above pre-processed data were imported into SCI2 for frequency statistics and co-word network generation (.net format). Then, the .net file was imported into the network analysis tool Pajek to calculate network indicators, including centralization (centrality), density, and the clustering coefficient, and to perform community segmentation to identify major sub-directions. The centralization refers to the centripetal or consistency of the co-word network as a whole, while centrality reflects the keywords’ position in the network and its ability to influence and control the network. The density represents the degree of association of the network as a whole, and the stronger the association, the more mature the research field; the clustering coefficient reflects the possibility that words will cluster into classes depending on the association and its strength, and the possibility that the network will be distinctly divided into several sub-networks or sub-classes. Combined with the community segmentation algorithm (Louvain), the co-word network will be divided into distinctive communities, each of which represents a sub-direction. With strong ties within the communities and loose ties between the communities, reflecting a greater concentration or consistency in the connotative associations of words within the community. Keywords are tightly linked within communities and loosely linked between communities, reflecting that keywords possess more focused or consistent connotations within communities.

### 3.3 Mapping and Visualization

To show the structure and characteristics of the TKIs research more intuitively and clearly, we visualized the topology, evolutionary venations, and development trend of the co-word network.

First, the visualization of the network topology. In this paper, Vosviewer was used for the multi-level presentation of co-word networks and communities, including the inter-community and intra-community association network graphs. In the network graphs, nodes represent keywords or communities, and edges represent co-occurrence relationships between words or communities. The size of nodes and the thickness of lines are proportional to the frequency of keywords and the scale of communities, respectively, and the nodes and lines belonging to different communities are distinguished by different colors. These network diagrams visualize the importance and association relationships of keywords or communities in TKIs and help to analyze the distribution and structural
characteristics of TKIs research. Second, the visualization of evolutionary venations. In this paper, we divided each year’s records into several communities. Then we used Cortext to calculate the overlapping relationships between communities in adjacent years and connected them through "tubes". In the tube diagram, bars of different colors and sizes represent communities of different sizes, and the tubes connected by several bars represent the continuation of the research theme, which can be considered as evolutionary venations. The evolutionary trends of TKIs research over time are visualized by graphically characterizing the continuity, convergence, and divergence of communities.

Third, the visualization of the developmentary degree of the sub-directions of TKIs research. These research communities can be considered as sub-directions of TKIs research, and each community or sub direction exhibits specific development status depending on the density and centrality. So, we drew a two-dimensional strategic diagram based on the calculation of the density and centrality of each community. The strategic diagram took centrality, which represented the core degree of research directions in TKIs, as the horizontal axis, and density, which represented the developmental maturity of research directions, as the vertical axis, and the mean of community density and centrality as the origin. Ultimately, communities were mapped into 4 quadrants to visualize the degree of centrality and maturity of different research directions in TKIs.

Fourth, the visualization of burst words. The changes in keyword frequency fluctuate significantly, with some of the words appearing in sudden bursts, reflecting the existence of distinct epochal characteristics of TKIs research. Therefore, we detected keyword bursts and combined their burst weights and durations to reveal changes in the focus of TKIs research.

4. Results

4.1 Themes involved in TKIs research

We extracted 10,956 unique keywords from the 5,584 available paper titles, and their total frequency was 28,743 (Figure 2). After pre-processing, 6,782 unique words with a total frequency of 26,175 were left. After several rounds of testing and discussion, the threshold value of high-frequency words was taken as 10 in this paper. So after merging the keywords with frequencies lower than 10 into their superordinate words, we finally obtained 296 keywords for the subsequent co-word analysis (Table 1). These 296 keywords whose total frequency accounted for 65.41% (17,120/26,175), can represent the mainstream of TKIs research in the past 5 years and can also reflect a strong concentration trend of TKIs research.

Figure 2. Yearly number of papers and words related to TKIs research (2016-2020)

Table 1. Top 100 keywords in papers related to TKIs research

| Ranking | Words                          | Frequency | Ranking | Words         | Frequency |
|---------|--------------------------------|-----------|---------|---------------|-----------|
| 1       | Non-small Cell Lung Cancer     | 1344      | 51      | Metabolism    | 76        |
| 2       | EGFR                           | 916       | 52      | Angiogenesis  | 73        |
| 3       | Chronic Myeloid Leukemia       | 586       | 53      | Overall Survival | 72        |
| ID  | Term                                      | Value   | Description                                      | Page |
|-----|-------------------------------------------|---------|--------------------------------------------------|------|
| 4   | EGFR-TKI                                  | 506     | Adenocarcinoma                                   | 72   |
| 5   | EGFR Mutation                            | 404     | T790M Mutation                                   | 71   |
| 6   | Lung Cancer                               | 370     | Met                                              | 70   |
| 7   | Erlotinib                                 | 299     | Lapatinib                                        | 68   |
| 8   | Imatinib                                  | 283     | Adverse Event                                    | 68   |
| 9   | Osimertinib                               | 261     | Molecular Docking                                | 67   |
| 10  | Gefitinib                                 | 257     | Carcinoma                                        | 66   |
| 11  | Targeted Therapy                          | 256     | Meta-analysis                                     | 64   |
| 12  | Renal Cell Carcinoma                      | 227     | Circulating Tumor DNA                            | 60   |
| 13  | Sunitinib                                 | 219     | Autophagy                                        | 59   |
| 14  | Lung Adenocarcinoma                       | 207     | Sarcoma                                          | 58   |
| 15  | Mutation                                 | 201     | Combination Therapy                              | 58   |
| 16  | Resistance                                | 192     | Acute Myeloid Leukemia                           | 58   |
| 17  | Afatinib                                  | 186     | Icotinib                                         | 58   |
| 18  | Chemotherapy                              | 183     | Leukemia                                         | 55   |
| 19  | Cancer                                    | 175     | VEGFR2                                           | 55   |
| 20  | Dasatinib                                 | 162     | Oncology                                         | 53   |
| 21  | Drug Resistance                           | 159     | Cabozantinib                                     | 52   |
| 22  | T790M                                    | 156     | Molecular Response                               | 52   |
| 23  | ALK                                       | 156     | Ponatinib                                        | 52   |
| 24  | Brain Metastasis                          | 136     | Liquid Biopsy                                    | 51   |
| 25  | Tumor                                    | 134     | Renal Cancer                                     | 51   |
| 26  | BCR-ABL                                   | 128     | Acute Lymphoblastic Leukemia                     | 50   |
| 27  | Nilotinib                                 | 121     | Plasma                                           | 48   |
| 28  | Crizotinib                                | 120     | Epithelial-mesenchymal Transition                | 48   |
| 29  | HER2                                      | 119     | VEGFR-TKI                                        | 48   |
| 30  | Apoptosis                                 | 113     | Drug-drug Interaction                            | 47   |
| 31  | Metastasis                                | 111     | PD-L1                                            | 47   |
| 32  | Acquired Resistance                       | 111     | VEGFR                                            | 47   |
| 33  | Sorafenib                                 | 109     | Clinical Trial                                   | 47   |
| 34  | Prognosis                                 | 107     | EGFR-TKI Resistance                              | 46   |
| 35  | Breast Cancer                             | 107     | Axitinib                                         | 46   |
| 36  | Pharmacokinetics                          | 107     | Philadelphia Chromosome                           | 45   |
| 37  | Pazopanib                                 | 106     | P-glycoprotein                                   | 45   |
| 38  | Next-generation Sequencing                | 96      | TKI Resistance                                   | 44   |
| 39  | Hepatocellular Carcinoma                  | 92      | Therapeutic Drug Monitoring                      | 44   |
| 40  | Gastrointestinal Stromal Tumor            | 92      | Sequencing                                       | 43   |
| 41  | Lenvatinib                                | 92      | Neratinib                                        | 43   |
| 42  | Apatinib                                  | 91      | Receptor Tyrosine Kinase                         | 43   |
| 43  | Immunotherapy                             | 91      | Brutons Tyrosine Kinase                          | 43   |
| 44  | Toxicity                                  | 89      | Immune Checkpoint Inhibitor                      | 43   |
| 45  | Metastatic Renal Cell Carcinoma           | 80      | Small Cell Lung Cancer                           | 42   |
| 46  | Radiotherapy                              | 80      | Molecular Targeted Therapy                       | 41   |
| 47  | VEGF                                      | 78      | Thyroid Cancer                                   | 41   |
| 48  | Ibrutinib                                 | 78      | Case Report                                      | 41   |
| 49  | Progression-free Survival                 | 77      | ROS1                                             | 40   |
| 50  | Biomarker                                 | 76      | c-Met                                            | 39   |

https://preprints.jmir.org/preprint/34548 [unpublished, non-peer-reviewed preprint]
Burst keywords can represent important changes in TKIs research. Figure 3 showed a varying number of burst words in TKIs research each year, whose duration expressed in terms of the length of the horizontal bar and weight in terms of the area. As can be seen from figure 3, a variable number of emergent terms have appeared in TKIs research every year since 2016, especially in 2019 and 2020, indicating the emergence of new research themes in this field every year. And the greater weight of burst words in 2020-2021 (e.g., HER2, Pyrotinib, Next-generation Sequencing, COVID-19, Immunotherapy, ALK-TKI, ALK Rearrangement, Cell-free DNA, Liquid Biopsy, Personalized Medicine), suggests that these words in TKIs research were extensively explored by researchers in 2020.

4.2. Correlation structure of keywords in TKIs research

Our analysis revealed that the co-word network consisting of the above 296 keywords was exactly the maximal connected subgraph, i.e., none of the high-frequency words in TKIs research is isolated, and all of them have paths associated with others, indicating that the research topics in this field form a whole that is interrelated and interact with each other.

4.2.1 Indicators of the correlation network

The overall indicators of the co-word network are shown in Table 2. The average degree of the network is 49.58, which means that a keyword in TKIs research is directly associated with 49.58 other keywords on average. These 49.58 keywords represent 16.75% of the entire network, which is a relatively small percentage, indicating that the range of inter-topic associations in TKIs research is not extensive. The high degree centralization of the network indicates a strong tendency to be...
centripetal or concentrated; the high closeness centralization and low betweenness centralization indicates that keywords are most directly related to each other rather than indirectly related; the high clustering coefficient indicates that keywords are likely to cluster into communities with certain words as the core. Collectively, TKIs research has clustered in certain specific sub-directions in recent years, between which the distinction is obvious. However, the density of the current co-word network is not high, i.e., the keywords are not closely related to each other, which indicates that TKIs research is more seriously fragmented and does not form a unified and mature research identity. We further divided the TKIs co-word network into six communities and calculated the module degree to ensure a good division.

**Table 2.** The whole network indicators

| Indicators                                      | Value  |
|------------------------------------------------|--------|
| Number of nodes                                | 296    |
| Number of lines                                | 7338   |
| Average degree                                 | 49.581 |
| Network All Degree Centralization              | 0.5953 |
| Network All Closeness Centralization           | 0.5265 |
| Network Betweenness Centralization             | 0.0525 |
| Network Clustering Coefficient                 | 0.4702 |
| Density                                        | 0.1681 |
| Number of Communities                          | 6 (Modularity: 0.3062) |

The network indicators of the keywords reflected their position and role in the TKIs co-word network (Table 3). Non-small Cell Lung Cancer, EGFR, Targeted Therapy, Lung Cancer, EGFR-TKI, Erlotinib, Chemotherapy, Cancer, Sunitinib, and Resistance all appear in the top 10 list of degree centralization and closeness centralization. The research topics associated with these words play an important role and have a strong influence on the whole field, while other words are likely to be clustered into a community with the above words as the core, forming a distinctive research sub-direction. In addition to Resistance, the above words also appear in the top 10 list of betweenness centralization, which serves as "bridges" in TKIs research, suggesting that more collaborations or synergies between TKIs research need to pass through these terms.

**Table 3.** Top-10 keywords in terms of degree, betweenness, and closeness centrality

| Ranking | Words                  | Degree | Words                  | Closeness | Words                  | Betweenness |
|---------|------------------------|--------|------------------------|-----------|------------------------|-------------|
| 1       | Non-small Cell Lung Cancer | 224    | Non-small Cell Lung Cancer | 0.8060    | Non-small Cell Lung Cancer | 0.0552     |
| 2       | EGFR                   | 204    | EGFR                   | 0.7642    | EGFR                   | 0.0397     |
| 3       | Targeted Therapy       | 180    | Targeted Therapy       | 0.7195    | Targeted Therapy       | 0.0346     |
| 4       | Lung Cancer            | 179    | Lung Cancer            | 0.7178    | Lung Cancer            | 0.0320     |
| 5       | EGFR-TKI               | 166    | EGFR-TKI               | 0.6958    | Lung Cancer            | 0.0291     |
| 6       | Erlotinib              | 164    | Erlotinib              | 0.6925    | EGFR-TKI               | 0.0251     |
| 7       | Chemotherapy           | 161    | Chemotherapy           | 0.6876    | Erlotinib              | 0.0216     |
| 8       | Cancer                 | 153    | Cancer                 | 0.6751    | Sunitinib              | 0.0214     |
| 9       | Sunitinib              | 151    | Sunitinib              | 0.6720    | Imatinib               | 0.0211     |
| 10      | Resistance             | 142    | Resistance             | 0.6585    | Cancer                 | 0.0206     |

4.2.2 Analysis of thematic communities

Depending on the association between keywords, TKIs are divided into six clusters or communities with certain important terms at their core. They are C1-Non-small Cell Lung Cancer, C2-Targeted Therapy, C3-Chronic Myeloid Leukemia, C4-HER2, C5-Pharmacokinetics, and C6-ALK (Table 4). These six communities represent the sub-directions of TKIs research in 2016-2020.
They are each closely associated within but loosely associated with each other.

In terms of size, the sub-directions of TKIs research can be divided into 3 echelons (Table 5). The first echelon includes C1-Non-small Cell Lung Cancer, which contains EGFR, EGFR-TKI, EGFR Mutation, Lung Cancer, Erlotinib, etc., and C2-Targeted Therapy, which contains Renal Cell Carcinoma, Sunitinib, Chemotherapy, Cancer, Tumor, etc. These two major sub-directions contain the largest number of keywords and the largest sum of frequencies, which are the main sub-directions of TKIs research. The second echelon includes C3-Chronic Myeloid Leukemia, which contains Imatinib, Dasatinib, BCR-ABL, Nilotinib, Gastrointestinal Stromal Tumor, etc., C4-HER2, which contains Apoptosis, Breast Cancer, Lapatinib, Autophagy, Combination Therapy, etc. and C5-Pharmacokinetics, which contains Ibrutinib, Metabolism, Molecular Docking, Plasma, Drug-drug Interaction, etc. These three communities are involved in research topics that are also important for TKIs research. Keywords from these three communities are also important themes in TKIs research. The third echelon only contains C6-ALK, including Crizotinib, Met, Receptor Tyrosine Kinase, ROS1, and ALK-TKI. C6 is still in its infancy, which occupies only a little weight in TKI research.

The varying centrality and density of each community further illustrate that there are sharply differentiated sub-directions in TKIs research (Table 5). For example, C1-Non-small Cell Lung Cancer and C2-Targeted Therapy have the highest centrality, which are the core sub-directions in TKIs research. And C1-Non-small Cell Lung Cancer and C2-Targeted Therapy also have the highest density and are the most developed sub-directions in TKI research. Furthermore, the internal density of each community is higher than the density of the whole TKIs co-word network, which also indicates that each sub-direction is tightly connected internally but loosely connected to each other. The centrality and density of C6-ALK do not have comparative value due to its small size.

Table 4. Topic communities related to TKIs research

| Community | Words |
|-----------|-------|
| C1-64     | Non-small Cell Lung Cancer; EGFR; EGFR-TKI; EGFR Mutation; Lung Cancer; Erlotinib; Osimertinib; Gefitinib; Lung Adenocarcinoma; Mutation; Resistance; Afatinib; Drug Resistance; T790M; Brain Metastasis; Acquired Resistance; Next-generation Sequencing; Adenocarcinoma; T790M Mutation; Circulating Tumor DNA; Icotinib; Liquid Biopsy; Epithelial-mesenchymal Transition; EGFR-TKI Resistance; Sequencing; Small Cell Lung Cancer; Case Report; Bevacizumab; Gefitinib Resistance; Pemetrexed; Squamous Cell Carcinoma; KRAS; Epidermal Growth Factor; Real-world Study; Leptomeningeal Metastasis; Advanced NSCLC; Cost-effectiveness; Rebiopsy; Dacomitinib; IGF-1R; STAT3; Droplet Digital PCR; Whole-brain Radiotherapy; Pleural Effusion; BIM; Uncommon Mutation; Polymorphism; Met Amplification; First-line Treatment; EGFR Exon 20; Computed Tomography; Cell-free DNA; TP53; Radiosurgery; Cisplatin; Docetaxel; Leptomeningeal Carcinomatosis; Skin Rash; Exosomes; Cerebrospinal Fluid; exon 19 Deletion; exon 19; Cetuximab; Metformin |
**C2-97** Targeted Therapy; Renal Cell Carcinoma; Sunitinib; Chemotherapy; Cancer; Tumor; Metastasis; Sorafenib; Prognosis; Pazopanib; Hepatocellular Carcinoma; Lenvatinib; Apatinib; Immunotherapy; Toxicity; Metastatic Renal Cell Carcinoma; Radiotherapy; VEGF; Progression-free Survival; Biomarker; Angiogenesis; Overall Survival; Adverse Event; Carcinoma; Meta-analysis; Sarcoma; VEGFR2; Oncology; Cabozantinib; Renal Cancer; VEGFR-TKI; PD-L1; VEGFR; Clinical Trial; Axitinib; Immune Checkpoint Inhibitor; Molecular Targeted Therapy; Thyroid Cancer; FGFR; PDGFR; Phase I Clinical Trial; Cardiotoxicity; Vandetanib; Regorafenib; Angiogenesis Inhibitor; PD-1; Ovarian Cancer; Colorectal Cancer; Hypertension; Anlotinib; Bone Metastasis; MicroRNA; Recurrence; Soft Tissue Sarcoma; mTOR; Hypoxia; Anti-angiogenesis; Nivolumab; Prognostic Factor; AXL; RET; Phase II Clinical Trial; Everolimus; Melanoma; Anaplastic Thyroid Cancer; Differentiated Thyroid Cancer; Receptor TKI; Clear Cell Renal Cell Carcinoma; Medullary Thyroid Cancer; Cancer Therapy; mTOR Inhibitor; Kidney; Adjuvant; Tumor Microenvironment; Solid Tumor; Treatment Response; Multitargeted TKI; Neutrophil-lymphocyte Ratio; Toceranib; Multikinase Inhibitor; Antiangiogenic Therapy; Monoclonal Antibody; Sequential Treatment; Osteosarcoma; Neoplasm Metastasis; Tolerability; Esophageal Cancer; Hypothyroidism; Circulating Tumor Cell; Neoadjuvant Therapy; Met TKI; PDGF; Paclitaxel; Neuroblastoma; Oligoprogession; Cervical Cancer; Pembrolizumab

**C3-46** Chronic Myeloid Leukemia; Imatinib; Dasatinib; BCR-ABL; Nilotinib; Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Leukemia; Molecular Response; Ponatinib; Acute Lymphoblastic Leukemia; Philadelphia Chromosome; TKI Resistance; FLT3; Kit; Quality Of Life; Adherence; Head And Neck Squamous Cell Carcinoma; Imatinib Resistance; Stem Cell Transplantation; Leukemia Stem Cell; Bosutinib; Stem Cell; Ph’ALL; Treatment-free Remission; Protein Kinase Inhibitor; Pulmonary Arterial Hypertension; Minimal Residual Disease; PDGFRα; Discontinuation; T315I; Adverse Drug Reaction; Chronic Phase; Cytokine; Interferon; c-KIT; Midostaurin; Single Nucleotide Polymorphism; Ruxolitinib; BCR-ABL Mutation; Kit Mutation; Treatment Discontinuation; Rechallenge; Src Tyrosine Kinase; BCR-ABL TKI; Patient-reported Outcome

**C4-38** HER2; Apoptosis; Breast Cancer; Lapatinib; Autophagy; Combination Therapy; Neratinib; c-Met; Gastrointestinal Cancer; Glioblastoma; AKT; Proliferation; Nanoparticles; ERK; Pancreatic Cancer; Reactive Oxygen Species; Cancer Stem Cell; Chemoresistance; Src; Hepatotoxicity; Oxidative Stress; Cell Cycle; Pyrotinib; Radiation; PI3K; Mitochondria; Trastuzumab; Migration; NF-kappa B; Gemcitabine; Drug Delivery; Glioma; Triple-negative Breast Cancer; Diarrhea; Adjuvant Therapy; Metastatic Breast Cancer; PI3K/AKT; Invasion

**C5-37** Pharmacokinetics; Ibrutinib; Metabolism; Molecular Docking; Plasma; Drug-drug Interaction; P-glycoprotein; Therapeutic Drug Monitoring; Brutons Tyrosine Kinase; BTK Inhibitor; Nintedanib; Chronic Lymphocytic Leukemia; Positron Emission Tomography; LC-MS/MS; Personalized Medicine; Anticancer; Lymphoma; Breast Cancer Resistance Protein; Interstitial Lung Disease; Spleen Tyrosine Kinase; Multidrug Resistance; Molecular Dynamics; Antitumor; Lung; Inflammation; Diabetes; Anticancer Drug; BCL-2; Bioavailability; Synthesis; Human Plasma; Mantle Cell Lymphoma; Idiopathic Pulmonary Fibrosis; Virtual Screening; UPLC-MS/MS; Pulmonary Fibrosis; Blood-brain Barrier

**C6-14** ALK; Crizotinib; Met; Receptor Tyrosine Kinase; ROS1; ALK-TKI; Alectinib; ALK Rearrangement; Immunohistochemistry; Lorlatinib; BRAF; Ceritinib; Resistance Mutation; Brigatinib

*Note: Keywords in each community are listed in descending order of frequency.*

| Community                        | Number of nodes | Number of lines | Total frequency | Average degree | Density  |
|----------------------------------|-----------------|-----------------|----------------|----------------|----------|
| C1-Non-small Cell Lung Cancer    | 64              | 817             | 7106           | 61.8438        | 0.3989   |

**Table 5. Indicators of 6 theme communities in TKIs research.**

https://preprints.jmir.org/preprint/34548

[unpublished, non-peer-reviewed preprint]
4.2.3 Visualization of the correlation network

The diverse correlation structure within and between each sub-direction of the TKIs research is visualized in Figure 4 and Figure 5. Figure 4 shows that there are differences in the influence of varied sub-directions and that the association between these sub-directions is uneven. C1-Non-small Cell Lung Cancer and C2-Targeted Therapy have the strongest associations with the other sub-directions, which reflect the strong influence of these two directions in TKIs research. The other four sub-directions are oriented to C1 and C2, or depend on them to varying degrees. The association between C1 and C2 is significantly stronger than that between other sub-directions, so C1 and C2 are the mainstream of current TKIs research. In particular, C1 is the most central and influential sub-direction in the whole TKIs research, and the associations between C1 and other directions are generally strong. Isolated C6-ALK is not strongly associated with any other sub-direction except for a closer association with C1.

Figure 5 further shows the correlation structure within each sub-direction, where each term has a different location, function, and role. Each sub-direction has a clear hierarchy, with the most influential terms at the core, which are important research themes, and the more distant from the core of the community, the less important the terms are. For example, EGFR, EGFR-TKI, EGFR Mutation, Lung Cancer, and Erlotinib are important research themes in C1-Non-small Cell Lung Cancer, which are closely related to the other terms or extended to other themes.
4.3 Evolution patterns of and trends in TKIs research

4.3.1 The evolutionary venations of research themes

Figure 6 illustrates the historical evolution of TKIs research themes, which includes both the scale and the clear evolutionary venation of TKIs research themes. Overall, there are clear sub-directions and good continuity of TKIs research from 2016 to 2020, but their size and distribution are uneven. In descending order of size, several major evolutionary venations are the Non-small Cell Lung Cancer venation (involving Apoptosis, Gefitinib, Osimertinib, EGFR-TKI, T790M Mutation, etc.), the Chronic Myeloid Leukemia venation (involving BCR-ABL, Dasatinib, Nilotinib, etc.), the Renal Cell Carcinoma venation (involving Sunitinib, Angiogenesis, Sorafenib, Regorafenib, Pazopanib, Immunotherapy, etc.), the Chronic Lymphocytic Leukemia venation (involving Lymphoma, Brutons Tyrosine Kinase, Ibrutinib, BTK Inhibitor, etc.), and the Lapatinib venation (involving Breast Cancer, Next-generation Sequencing, ALK Rearrangement, ALK, Alectinib, etc.). There are also isolated, intermittent research themes, such as Crizotinib & ALK in 2016, apoptosis & PI3K/AKT in 2017, Molecular Docking & Anticancer in 2019, and Cabozantinib & AXL in 2020 for the first time as a sub-direction.
4.3.2 The developmentary degree of the sub-directions of TKIs research

Based on Table 5, we draw a strategic diagram (Figure 7) to visualize the developmentary trends of the sub-directions in TKIs research. The C6 community wasn’t drawn in the strategy diagram due to its small size and non-comparable network indicators. As shown in Figure 7, we plotted the nodes of different sizes to represent the total frequencies of the varied sub-directions of TKIs research and distributed them in four quadrants according to their density and centrality. C1-Non-small Cell Lung Cancer is in the first quadrant due to its high density and centrality, again indicating that this community is the core direction and most developed in TKIs research. C2-Targeted Therapy is located exactly at the junction of the first and fourth quadrants, which means that C2 is also the core direction of TKIs research, but is in the process of maturing. C3-Chronic Myeloid Leukemia, C4-HER2, and C5-Pharmacokinetics are all in the third quadrant, with relatively low centrality and density, which indicates that they are at the margins of TKIs research and are immature.

5. Discussion

With the continuous progress of medicine, the targeted drugs TKIs have made great development...
in basic research and have been widely used for clinical applications. Based on the results of the co-word analysis, we have a better understanding of the main research directions of TKIs and accurately assess their maturity, centrality, and interactions. First, in general, TKIs research is unbalanced. Since the first TKIs were introduced, researchers have focused on some hot terms such as NSCLC, EGFR, CML, EGFR-TKI, EGFR Mutation, Erlotinib, Imatinib, Osimertinib, Gefitinib, Targeted Therapy, Renal Cell Carcinoma, Resistance, etc. The above terms can be broadly classified into the following categories: clinical applications (e.g., NSCLC, CML, Renal Cell Carcinoma, Lung Adenocarcinoma), genetic studies (e.g., EGFR, EGFR Mutation, BCR-ABL), typical drugs (e.g., Erlotinib, Imatinib, Gefitinib, Sunitinib, Afatinib, Dasatinib, Osimertinib, Nilotinib), and chemotherapy and drug resistance (e.g., Targeted Therapy, Resistance, Chemotherapy, Drug Resistance). These terms not only reflect the areas of interest of researchers but also indicate the trends of TKIs research.

Based on the visualized co-word network, we found that the research topics tend to be clustered around a few keywords, eventually forming a hierarchical and relatively balanced thematic community. The thematic communities of the TKIs consist of C1-Non-small Cell Lung Cancer, C2-Targeted Therapy, C3-Chronic Myeloid Leukemia, C4-HER2, C5-Pharmacokinetics, and C6-ALK. First, the C1 and C2 communities are the main areas of TKIs research because of their high centrality and frequency. Among them, C1-NSCLC, the largest thematic community, has received a lot of attention from scholars. From gene targets (e.g., KRAS, EGFR, TP53, BIM) to signaling pathways (e.g., IGF-1R, STAT3), from conventional chemotherapy (e.g., Cisplatin, Docetaxel, Pemetrexed) to targeted drugs (e.g., Erlotinib Osimertinib, Gefitinib), scholars have studied NSCLC more and more deeply. C2-Targeted Therapy indicates that TKIs are widely used in targeted therapies, and the application of TKIs has been extended to lung cancer\(^\text{12, 31, 32}\), breast cancer\(^\text{64}\), renal cancer\(^\text{65, 66}\), liver cancer\(^\text{67}\), ovarian cancer\(^\text{68}\), colorectal cancer\(^\text{69}\), leukemia\(^\text{11, 28, 29}\), thyroid cancer\(^\text{70, 71}\), cervical cancer\(^\text{72}\) and many other tumors. Chemotherapy regimens containing TKIs were effective in reducing tumor metastasis and recurrence and improving the OS of patients\(^\text{12, 31}\). The use of TKIs will be further expanded to more tumor types as more clinical trials are conducted.

Second, C3 and C5 communities have declined during the development of TKIs, both of which are in a marginal position in the strategic diagram. Among C3-Chronic Myeloid Leukemia, Imatinib is the first targeted anti-tumor drug that was first approved by the FDA in 2001 for patients with BCR-ABL positive CML\(^\text{10, 11, 28, 29, 73}\). With the emergence of drug resistance, Dasatinib\(^\text{74}\), which targets the SRC, and nilotinib\(^\text{75}\), which targets BCR-ABL, have been applied to resistant patients. Research on CML has been conducted for a long time and this field is now mature, so the application of TKIs has gradually expanded from CML to other diseases, which is leading to the gradual marginalization of the C3 community. C5-Pharmacokinetics is an important interdisciplinary discipline related to TKIs, which is widely involved in the development process of TKIs\(^\text{76, 77}\). However, as small molecule drugs, the absorption, transport, distribution, and transformation of most TKIs in vivo have been clearly studied. Meanwhile, several new technologies in molecular biology (e.g., molecular docking\(^\text{79}\) and virtual high-throughput screening\(^\text{79}\)) are used more and more, so C5-Pharmacokinetics is gradually fading.

Despite the gradual decline of the C3 and C5 communities, new research areas such as C4-HER and C6-ALK have flourished in recent years. The overexpression, amplification, and mutations of HER2 have been found in a variety of tumors including breast cancer and NSCLC\(^\text{45}\), and targeting HER2 has achieved excellent efficacy in breast cancer\(^\text{64}\). Although several early drugs targeting HER2 had poor efficacy in NSCLC\(^\text{34, 36, 45}\), the advent of newer generation HER2-targeting drugs such as poziotinib\(^\text{80}\), pyrotinib\(^\text{81, 82}\) exhibited good anti-tumor effects in clinical trials. Scholars are increasingly interested in targeting HER2 in NSCLC, while research on HER2 for breast cancer is relatively well established. Therefore, C4 may evolve in different directions in the future respectively. The C6-ALK community is small but promising. ALK mutations, especially rearrangements, exhibit strong translational activity in NSCLC\(^\text{83}\). ALK-targeted agents such as
alectinib and brigatinib have shown extraordinary efficacy in ALK-positive NSCLC and have become the first-line therapies. Lorlatinib, an ALK inhibitor, appears as a burst word in 2020, and ALK-TKI and ALK Rearrangement have a high weight in Figure 3 from 2019 to 2020, both of which indicate the rapidly rising heat of ALK. In addition, there are still several ALK-targeted drugs in development, so more literature on ALK will be published in the future and the C6 community will grow further.

We found several evolutionary venations, by analyzing the evolution of themes of TKIs research over time. These highly concentrated evolutionary venations indicate scholars’ continuous and steady focus on Non-small Cell Lung Cancer, Chronic Myeloid Leukemia, Renal Cell carcinoma, Chronic Lymphocytic Leukemia, etc. These different evolutionary lines show a clear development path: TKIs research is disease-focused and revolved around "gene targets/targeted drugs/resistance mechanisms". For example, in the Chronic Myeloid Leukemia venation, investigators focused on the BRC-ABL in 2016 and focused on dasatinib and nilotinib in 2017-2020, which could both target BCR-ABL and overcome imatinib resistance. In the Non-small Cell Lung Cancer venation, investigators focused on EGFR genes in 2016, on EGFR-TKIs represented by osimertinib in 2016, and on resistance mechanisms represented by T790M in 2020. In the Renal Cell carcinoma venation, investigators continued to focus on various TKIs such as sunitinib, sorafenib, regorafenib, and pazopanib, and investigators also paid attention to gene targets such as PDGFR, FGFR, c-Kit, and VEGF, and multidrug resistance. In the Chronic Lymphocytic Leukemia venation, investigators focused on B-cell-derived CLL and lymphoma in 2016, on the aberrant Bruton tyrosine kinase (BTK) from B cells in 2017, and on BTK inhibitors such as ibrutinib that can treat CLL and lymphoma in 2018-2020. Moreover, Lapatinib, a dual EGFR/HER2 TKI, showed good efficacy in breast cancer, which made it an independent evolutionary venation in 2017 with continues heat to now.

In addition to the main few evolutionary venations, we identified some isolated themes that depict the current state of TKIs research. Crizotinib gained attention as an ALK inhibitor in 2016, but Crizotinib's declined rapidly due to its poor efficacy and the emergence of second-generation ALK inhibitors, making Crizotinib & ALK an isolated topic. Circulating Tumor DNA (ctDNA) is important for the efficacy assessment and prognosis analysis of tumors. And it’s the future trend in TKIs research to use NGS or liquid biopsy technology to precisely analyze ctDNA in cell-free DNA. The PI3K/AKT pathway plays an important role in cell growth, proliferation, migration, and angiogenesis, which can be activated by RTKs. So as one of the mechanisms of TKIs, the apoptosis & PI3K/AKT venation was noticed in 2017-2018. Cabozantinib is a multi-target TKIs that can target 9 genes (e.g., AXL, Met), and Cabozantinib & AXL appeared as a separate topic in 2020. Furthermore, the burst words pyrotinib and anlotinib, which accounted for a relatively large weight in 2020, are also multi-target inhibitors. This suggests that multi-target drugs may become an important direction for the development of TKIs and will likely receive more attention in the future. Immune checkpoint inhibitors and TKIs are important drugs for tumors. It’s discovered that the combination of PD-L1 inhibitors (e.g., Pembrolizumab) and TKIs (e.g., Lenvatinib) in patients with malignant tumors was more effective than single drug, suggesting that the combination therapy was an important development direction for future tumor therapy. For well-known reasons, many patients being treated with TKIs were co-infected with SARS-COV-2 in 2020, and it was also suggested that some TKIs such as BTKs may have therapeutic effects on COVID-19, which made COVID-19 a burst word in TKIs research. As the global epidemic of COVID-19 in 2021, investigators’ interest in TKIs for patients infected with SARS-COV-2 would further increase.

6. Conclusions

In conclusion, we revealed the hotspots, knowledge structure, and trends of evolution of TKIs research during 2016-2020 utilizing co-word analysis and literature visualization. Based on the above results, we speculate that the general status of TKIs research is as follows: (1) NSCLC and CML are the most important clinical application areas for TKIs; (2) EGFR is the most common

https://preprints.jmir.org/preprint/34548
target gene for TKIs, and EGFR-TKIs are the most commonly used molecular-targeted TKIs, among which Erlotinib, Osimertinib, and Gefitinib have gradually matured; (3) TKIs have become a mature field for targeted therapeutic applications, and drugs targeting HER2 and ALK has further expanded the application of TKIs; (4) drug resistance remains a major challenge for TKIs. Of course, our study also has some limitations: first, our search included only English literature from 2016 to 2020, while non-English literature was excluded; second, the co-word analysis didn’t take the quality, influence, and rigor of the literature into account, which was a common shortcoming of such papers. In a nutshell, our work remains valuable in revealing the knowledge structure and evolutionary trends of TKIs research.

Acknowledgments
This study was supported by grants from Natural Science Foundation of Hubei Province (Grant No. 2020CFB611).

Authors’ Contributions
Designed this research: Jiming Hu Miao Liu, and Zhiwei Wang;
Developed the search strategy and screened the literature: Miao Liu and Jiming Hu;
Screened and processed the keywords: Kai Xing, Miao Liu, and Jiming Hu;
Participated in the data visualization: Jiming Hu and Yan Zhang;
Made the images and tables: Jiming Hu and Yan Zhang;
Wrote the manuscript: Miao Liu, Jiming Hu, and Kai Xing;
Translated the manuscript: Kai Xing;
Reviewed and revised the manuscript: Miao Liu and Zhiwei Wang
Jiming Hu, Kai Xing, and Yan Zhang are common first authors. Miao Liu and Zhiwei Wang are common communication authors.

Conflicts of Interest
The authors declare that there are no competing economic or commercial interests in this manuscript.

Abbreviations
TKs: tyrosine kinases
TKIs: tyrosinase inhibitors
RTKs: receptor tyrosine kinases
non-RTKs: non-receptor tyrosine kinases
EGFR: epidermal growth factor receptor
VEGFR: vascular endothelial growth factor receptor
ATP: adenosine triphosphate
NSCLC: non-small cell lung cancer
CML: chronic myeloid leukemia
NGS: Next-generation sequencing
WOSCC: Web of Science Core Collection
BTK: Bruton tyrosine kinase
ctDNA: Circulating Tumor DNA
References

1. Jo DH, Kim JH, Kim JH. Targeting tyrosine kinases for treatment of ocular tumors. *Arch Pharm Res*. Apr 2019;42(4):305-318. doi:10.1007/s12272-018-1094-3

2. Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. *Mol Cancer*. Feb 19 2018;17(1):58. doi:10.1186/s12943-018-0782-4

3. Siveen KS, Prabhu KS, Achkar IW, et al. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. *Mol Cancer*. Feb 19 2018;17(1):31. doi:10.1186/s12943-018-0788-y

4. An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. *Oncogene*. Mar 2018;37(12):1561-1575. doi:10.1038/s41388-017-0045-7

5. Ma Z, Yu YR, Badea CT, et al. Vascular endothelial growth factor receptor 3 regulates endothelial function through β-arrestin 1. *Circulation*. Mar 26 2019;139(13):1629-1642. doi:10.1161/circulationaha.118.034961

6. Losocco F, Visani G, Galimberti S, Curti A, Iodisi A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. *Front Oncol*. 2019;9:939. doi:10.3389/fonc.2019.00939

7. Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. *Front Immunol*. 2019;10:1862. doi:10.3389/fimmu.2019.01862

8. Morris TA, Khoo C, Solomon BJ. Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors. *Drugs*. Aug 2019;79(12):1277-1286. doi:10.1007/s40265-019-01164-3

9. Zeng P, Schmaier A. Ponatinib and other CML tyrosine kinase inhibitors in thrombosis. *Int J Mol Sci*. Sep 8 2020;21(18):10.3390/ijms21186556

10. Radich JP, Deiningen M, Abboud CN, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. 2018;16(9):1108. doi:10.6004/jnccn.2018.0071

11. Pallera A, Altman JK, Berman E, et al. NCCN guidelines insights: chronic myeloid leukemia, version 1.2017. 2016;14(12):1505. doi:10.6004/jnccn.2016.0162

12. Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. 2019;17(12):1464. doi:10.6004/jnccn.2019.0059

13. Wang S, Song Y, Liu D. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. *Cancer Lett*. Jan 28 2017;385:51-54. doi:10.1016/j.canlet.2016.11.008

14. Tan CS, Kumarakulasinge NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions. *Mol Cancer*. Feb 19 2018;17(1):29. doi:10.1186/s12943-018-0778-0

15. Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. *Ann Oncol*. Jan 2018;29(suppl_1):i20-i27. doi:10.1093/annonc/mdx704

16. Lyy X, Hu J, Dong W, Xu X. Intellectual structure and evolutionary trends of precision medicine research: coword analysis. *JMIR Med Inform*. Feb 4 2020;8(2):e11287. doi:10.2196/11287

17. Wei WJ, Shi B, Guan X, Ma JY, Wang YC, Liu J. Mapping theme trends and knowledge structures for human neural stem cells: a quantitative and co-word biclustering analysis for the 2013-2018 period. *Neural Regen Res*. Oct 2019;14(10):1823-1832. doi:10.4103/0973-9797.330999

18. Lu K, Yu S, Yu M, et al. Bibliometric analysis of tumor immunotherapy studies. *Med Sci Monit*. May 23 2018;24:3405-3414. doi:10.12659/msm.910724

19. Huang J, Tang J, Qu Y, et al. Mapping the knowledge structure of neonatal hypoxic-ischemic encephalopathy over the past decade: a co-word analysis based on keywords. *J Child Neurol*. May 2016;31(6):797-803. doi:10.1177/0883073815615673

20. An XY, Wu QQ. Co-word analysis of the trends in stem cells field based on subject heading weighting. *Scientometrics*. 2011/07/01 2011;88(1):133-144. doi:10.1007/s11192-011-0374-1

21. Wei W, Ge J, Xu S, et al. Knowledge maps of disaster medicine in china based on co-word analysis. *Disaster Med Public Health Prep*. Jun 2019;13(3):405-409. doi:10.1017/dmp.2018.63

22. Hsu W-C, Li J-H. Visualising and mapping the intellectual structure of medical big data. *Journal of Information Science*. 2019/04/01 2018;45(2):239-258. doi:10.1177/0165551518782824

23. Shen L, Wang S, Dai W, Zhang Z. Detecting the interdisciplinary nature and topic hotspots of robotics in surgery: social network analysis and bibliometric study. *J Med Internet Res*. Mar 26 2019;21(3):e12625. doi:10.2196/12625

24. Gan J, Cai Q, Galer P, et al. Mapping the knowledge structure and trends of epilepsy genetics over the past decade: a co-word analysis based on medical subject headings terms. *Medicine (Baltimore)*. Aug 2019;98(32):e16782. doi:10.1097/md.0000000000016782

25. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. *Eur J Pharmacol*. Sep 5 2018;834:188-196. doi:10.1016/j.ejphar.2018.07.034

26. Krajewski KM, Braschi-Amirfarzan M, DiPiro PJ, Jagannathan JP, Shinagare AB. Molecular targeted therapy in...
modern oncology: imaging assessment of treatment response and toxicities. Korean J Radiol. Jan-Feb 2017;18(1):28-41. doi:10.3348/kjr.2017.18.1.28
27. Claudiani S, Apperley JF. The argument for using imatinib in CML. Hematology Am Soc Hematol Educ Program. Nov 30 2018;2018(1):161-167. doi:10.1182/asheducation-2018.1.161
28. O’Brien S, Radich JP, Abboud CN, et al. Chronic myelogenous leukemia, version 1.2015. 2014;12(11):1590. doi:10.6004/jnccn.2014.1019
29. O’Brien S, Radich JP, Abboud CN, et al. Chronic myelogenous leukemia, version 1.2014. 2013;11(11):1327. doi:10.6004/jnccn.2013.0157
30. Rieder D, Finotello F. Analysis of high-throughput RNA bisulfite sequencing data. Methods Mol Biol. 2017;1562:143-154. doi:10.1007/978-1-4939-6807-7_10
31. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol. Oct 20 2017;35(30):3484-3515. doi:10.1200/jco.2017.74.6065
32. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. Sep 2016;27(suppl 5):v1-v27. doi:10.1093/annonc/mdw326
33. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. Jan 11 2018;378(2):113-125. doi:10.1056/NEJMoa1713137
34. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. Journal of Clinical Oncology. 2018/08/20 2018;36(24):2532-2537. doi:10.1200/jco.2018.77.9777
35. Mazieres J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Annals of Oncology. 2016/02/01/ 2016;27(2):281-286. doi:10.1093/annonc/mdw573
36. Heymach J, Negrao M, Robichaux J, et al. OA02.06 a phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2018/10/01/ 2018;13(10, Supplement):S323-S324. doi:10.1016/j.jtho.2018.08.243
37. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. Mar 4 2017;389(10072):917-929. doi:10.1016/s0140-6736(17)30123-x
38. Baccarani M, Druker BJ, Branford S, et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the tyrosine kinase inhibitor optimization and selectivity (TOPS) study. Int J Hematol. 2014;99(5):616-24. doi:10.1007/s12185-014-1566-2
39. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. Feb 24 2005;352(8):786-92. doi:10.1056/NEJMoa044238
40. Wu SG, Liu YN, Tsai MF, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. Mar 15 2016;7(11):12404-13. doi:10.18632/oncotarget.7189
41. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. Nov 1 2006;12(21):6494-501. doi:10.1158/1078-0432.Ccr-06-1570
42. Yamaguchi F, Fukuchi K, Yamazaki Y, et al. Acquired resistance L747S mutation in an epidermal growth factor receptor-mutant lung adenocarcinoma with acquired resistance to kinase inhibitors. Clin Cancer Res. Apr 16 2018;24(7):1759-7714.12613
43. Steins M, Thomas M, Geißler M, Eruotinib. Recent Results Cancer Res. 2018;211:1-17. doi:10.1007/978-3-319-91442-8_1
44. Rawluk J, Waller CF. Gefitinib. Recent Results Cancer Res. 2018;211:235-246. doi:10.1007/978-3-319-91442-8_16
45. Baraibara I, Mezquita L, Gil-Bazo I, Planchard D. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Critical Reviews in Oncology/Hematology. 2020/04/01/ 2020;148:102906. doi:10.1016/j.critrevonc.2020.102906
46. Wu X, Shao Y, Qin HF, Tai YH, Gao HJ. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. Apr 2018;9(4):423-430. doi:10.1111/1759-7714.12613
47. Dhillon S. Regorafenib: a review in metastatic colorectal cancer. Drugs. Jul 2018;78(11):1133-1144. doi:10.1007/s40265-018-0938-y
48. Hu J, Zhang Y. Research patterns and trends of recommendation system in china using co-word analysis.

https://preprints.jmir.org/preprint/34548 [unpublished, non-peer-reviewed preprint]
53. Alcaide Munoz L, Pedro Rodriguez-Bolivar M, Jesus Cobo M, Herrera-Viedma E. Analysing the scientific evolution of e-Government using a science mapping approach. Government Information Quarterly. Sep 2017;34(3):545-555. doi:10.1016/j.giq.2017.05.002
54. Boerner K. Plug-and-play macroscopes. Communications of the ACM. Mar 2011;54(3):60-69. doi:10.1145/1897852.1897871
55. Doreian P, Lloyd P, Mrvar A. Partitioning large signed two-mode networks: problems and prospects. Social Networks. May 2013;35(2):178-203. doi:10.1016/j.socnet.2012.01.002
56. Freeman LC. Centrality in social networks networks conceptual clarification. Social Networks. 1979;1979;1(3):215-239. doi:10.1016/0378-8733(78)90021-7
57. Yan E, Ding Y, Zhu Q. Mapping library and information science in China: a coauthorship network analysis. Scientometrics. Apr 2010;83(1):115-131. doi:10.1007/s11192-009-0027-9
58. Leydesdorff L, Park HW, Wagner C. International coauthorship relations in the social sciences citation index: is internationalization leading the network? Journal of the Association for Information Science and Technology. Oct 2014;65(10):2111-2126. doi:10.1002/asi.23102
59. Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E. Fast unfolding of communities in large networks. Journal of Statistical Mechanics-Theory and Experiment. Oct 2008;P10008. doi:10.1088/1742-5468/2008/10/p10008
60. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. Aug 2010;84(2):523-538. doi:10.1007/s11192-009-0146-3
61. Rosvall M, Bergstrom CT. Mapping change in large networks. Plos One. Jan 27 2010;5(1)e8694. doi:10.1371/journal.pone.0008694
62. Kleinberg J. Bursty and hierarchical structure in streams. Data Mining and Knowledge Discovery. Oct 2003;7(4):373-397. doi:10.1023/a:1024940629314
63. Newman MEJ, Girvan M. Finding and evaluating community structure in networks. Physical Review E, Feb 2004;69(2)026113. doi:10.1103/PhysRevE.69.026113
64. Wuerstlein R, Harbeck N. Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials. 2017;12(2):81-92. doi:10.2174/15748871112666170202165049
65. Shah AY, Kotecha RR, Lenke EA, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. Jun 2019;114:67-75. doi:10.1016/j.ejca.2019.04.003
66. Tannir NM, Pal SK, Atkins MB. Second-line treatment landscape for renal cell carcinoma: a comprehensive review. Oncologist. May 2018;23(5):540-555. doi:10.1634/theoncologist.2017-0534
67. Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. Mar-Apr 2019;9(2):221-232. doi:10.1016/j.jceh.2019.01.004
68. Liu J, Nicum S, Reichardt P, et al. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. Gynecol Oncol. Jul 2018;150(1):173-179. doi:10.1016/j.ygyno.2018.03.058
69. Kircher SM, Nimeiri HS, Benson AB, 3rd. Targeting angiogenesis in colorectal cancer: tyrosine kinase inhibitors. Cancer J. May-Jun 2016;22(3):182-9. doi:10.1097/ppco.0000000000000192
70. Ferrari SM, Centanni M, Virilli C, et al. Sunitinib in the treatment of thyroid cancer. Curr Med Chem. 2019;26(6):963-972. doi:10.2174/0929867324666171006165942
71. Porcelli T, Sessa F, Luongo C, Salvatore D. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer. J Endocrinol Invest. Aug 2019;42(8):871-879. doi:10.1007/s40618-019-1001-x
72. Lv Y, Cang W, Li Q, et al. Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. Oncogenesis. Nov 26 2019;8(12):70. doi:10.1038/s41389-019-0179-2
73. Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2018;212:1-27. doi:10.1007/978-3-319-91439-8_1
74. McCafferty EH, Dhillon S, Deeks ED. Dasatinib: a review in pediatric chronic myeloid leukemia. Paediatr Drugs. Dec 2018;20(6):593-600. doi:10.1007/s40272-018-0319-8
75. Sacha T, Saglio G. Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol. Mar 2019;15(9):953-965. doi:10.2217/fon-2018-0468
76. Suttorp M, Bornhäuser M, Metzler M, Millot F, Schleyer E. Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Rev Clin Pharmacol. Mar 2018;11(3):219-231. doi:10.1080/17512433.2018.1398644
77. Kucharczuk CR, Ganetsky A, Vozniak JM. Drug-drug interactions, safety, and pharmacokinetics of EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. J Adv Pract Oncol. Mar 2018;9(2):189-200.
78. Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. Sep 4 2019;20(18): doi:10.3390/ijms20184331
79. Geromichalos GD, Allifieris CE, Geromichalou EG, Trafalis DT. Overview on the current status on virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; part II. J buon. Nov-Dec 2016;21(6):1337-1358.
80. Robichaux JP, Elamin YY, Vijayan RSK, et al. Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell. 2019/10/14/ 2019;36(4):444-457.e7. doi:10.1016/j.ccell.2019.09.001
81. Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Annals of Oncology. 2019/03/01/ 2019;30(3):447-455. doi:10.1093/annonc/mdy542
82. Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol. Oct 2019;37(29):2610-2619. doi:10.1200/jco.19.00108
83. Soda M, Isobe K, Inoue A, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Article. Clinical Cancer Research. 2012;18(20):5682-5689. doi:10.1158/1078-0432.CCR-11-2947
84. Herden M, Waller CF. Alectinib. Recent Results Cancer Res. 2018;211:247-256. doi:10.1007/978-3-319-91442-8_17
85. Spencer SA, Riley AC, Matthew A, Di Pasqua AJ. Brigatinib: novel ALK inhibitor for non-small-cell lung cancer. Ann Pharmacother. Jun 2019;53(6):621-626. doi:10.1177/1060028018824578
86. Elsayed M, Christopoulos P. Therapeutic sequencing in ALK(+) NSCLC. Pharmaceuticals (Basel). Jan 21 2021;14(2):doi:10.3390/ph14020080
87. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. Nov 19 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187
88. Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2018;211:19-44. doi:10.1007/978-3-319-91442-8_2
89. Deeks ED. Cabozantinib: a review in advanced hepatocellular carcinoma. Target Oncol. Feb 2019;14(1):107-113. doi:10.1007/s11523-019-00622-y
90. Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. Sep 19 2018;11(1):120. doi:10.1186/s13045-018-0664-7
91. Taylor MH, Lee CH, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncr. Apr 2020;38(11):1154-1163. doi:10.1200/jco.19.01598
92. Başcı S, Ata N, Altuntaş F, et al. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. Oct 2020;26(7):1676-1682. doi:10.1177/1078155220953198
93. McGee MC, August A, Huang W. BTK/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy. J Leukoc Biol. Jan 2021;109(1):49-53. doi:10.1002/jlb.5covr0620-306r
94. Yao R-q, Ren C, Wang J-n, et al. Publication trends of research on sepsis and host immune response during 1999-2019: a 20-year bibliometric analysis. Review. International Journal of Biological Sciences. 2020;16(1):27-37. doi:10.7150/ijibs.37496
95. Lei F, Ye J, Wang J, Xia Z. A bibliometric analysis of publications on oxycodone from 1998 to 2017. Biomed Res Int. 2019;2019:9096201. doi:10.1155/2019/9096201
96. Zyoud SH, Smale S, Waring WS, Sweileh WM, Al-Jabi SW. Global research trends in microbiome-gut-brain axis during 2009-2018: a bibliometric and visualized study. BMC Gastroenterol. Aug 30 2019;19(1):158. doi:10.1186/s12876-019-1076-z
Supplementary Files
Figures
Search procedure for documents in TKIs research. DE descriptor; TI title; WOSCC Web of Science Core Collection.

Documents retrieved from WOSCC (n=13,895)

Bibliographic records downloaded from WOSCC (n=13,895)

Exclude records without keywords in DE field (n=2,845) and not containing search terms in TI and DE fields (n=3,394)

Bibliographic records (n=7,656)

Exclude records that are not related to TKI in manual way (n=2,072)

Determined records for this study (n=5,584)
Yearly number of papers and words related to TKIs research (2016-2020).
Burst disciplines of TKIs research from 2016 to 2021.
Correlation structure of sub-directions in TKIs research.
The internal correlation network structure of each sub-directions in TKIs research.
The evolution of themes of TKIs research over time (2016-2020).
The relative development status and trends of 5 sub-directions in the strategic diagram.